Lovastatin Inhibits Pancreatic Cancer Growth Regardless of RAS Mutation

Abstract excerpt

Lovastatin, an inhibitor of the rate-limiting enzyme of cholesterol synthesis, inhibits growth of pancreatic cancer cells. A possible mechanism of this inhibition is that lovastatin inhibits the activity of RAS protein by depleting farnesyl (an intermediate of cholesterol synthesis). The K-ras gene is frequently mutated in pancreatic cancers and RAS protein requires farnesyl to be bound to the cell membrane and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Lipids, and Metabolism
• Share to Inflammatory mediators and NSAID effects
• Share to Lipoproteins and Cardiovascular Health